Clinical Trial Update: IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of IGF-MTX Conjugate for myelodysplastic syndromes and related hematologic conditions has been terminated, with results posted in May 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia Refractory with Excess Blasts
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• IGF-MTX Conjugate (IGF-MTX Conjugate)

Snippet

Sponsor: IGF Oncology, LLC | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-05-21